GENOMIC TESTING

This week's best content includes oral HPV's role in SCCHN, a full clinical hold for pacritnib, immunotherapies in head and neck cancer, and more.

This is the "Conclusion and References" section of the current issue of Evolving Paradigms In Bladder Cancer.

This is the "Emerging Therapies" section of the current issue of Evolving Paradigms In Bladder Cancer.

This is the "Emerging Biomarkers" section of the current issue of Evolving Paradigms In Bladder Cancer.

This is the "Prognosis and Treatment" section of the current issue of Evolving Paradigms In Bladder Cancer.

This is the "Current Treatment Strategies" section of the current issue of Evolving Paradigms In Bladder Cancer.

This is the "Introduction" section of the current issue of Evolving Paradigms In Bladder Cancer.

A new method to elucidate the clonal relationship between tumors used tissues and clinical details from patients with contralateral breast cancer, and for the first time, next-generation sequencing.

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, talks about the importance of women knowing which genetic tests they�ve previously had done for breast cancer.

Daniel S. Oh, MD, assistant professor of surgery, University of Southern California, Keck School of Medicine, discusses myPlan genetic testing in patients with lung cancer.

Sonidegib (Odomzo) was approved by the EC for the treatment of patients who have locally advanced basal cell carcinoma (laBCC) and are not amenable to curative surgery or radiation therapy.

Stephen Rosenberg, MD, Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, discusses the possibility of writing information in a way that patients can understand.

Jonathan C. Trent, MD, PhD, professor of medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Health System, gives an overview of the NCI Molecular Analysis for Therapy Choice Program (MATCH).

PSA testing utilization decreased by 50% among primary care physicians at Oregon Health & Science University, following a recommendation against screening from the USPSTF.

Despite their promise, checkpoint inhibitors are not effective in every patient, and research suggests the STING (stimulator of interferon genes) pathway may hold important clues as to why some tumors fail to respond.

The availability of mutation-specific treatments and an increasing understanding of potential resistance mechanisms have provided immense opportunities for research and development of new therapies in lung cancer.

Despite the availability of several new agents in the past 5 years for the treatment of melanoma, patients with advanced melanoma still suffer poor prognoses.

Almost half of patients with cancer who receive genetic testing may be given information that leads to unsuitable targeted treatments, according to researchers from Johns Hopkins Kimmel Cancer Center.

A research team led by investigators at the University of Texas Southwestern Medical Center in Dallas has published a study in Nature Communications identifying several new genetic mutations in pancreatic ductal adenocarcinoma.

Sharyn N. Lewin, MD, discusses the importance of screening patients with ovarian cancer for a BRCA mutation.

Harold Varmus, MD, may be stepping down as director of the National Cancer Institute (NCI) at the end of March, but in an interview with Targeted Oncology, he made it clear that he is not retiring.

Blocking activin-A, a protein that is secreted by non-small cell lung cancer (NSCLC) cells, may prevent cancer metastasis, according to research conducted at the University of Virginia (UVA).

Many patients with non–small cell lung cancer (NSCLC) have no identifiable mutations, and therefore their disease cannot be managed with targeted treatments.

In the largest patient population study to date, Mayo Clinic investigators have identified new genetic predictors of toxicity to colon cancer treatment, but the study has some caveats.

Guardant360 is a highly sensitive digital sequencing system that requires only a 10 mL blood sample, and allows for simultaneous assessment of more than 60 actionable genes in circulating, cell-free DNA.